British AI company BenevolentAI and pharma major AstraZeneca have moved forward their 2019-initiated drug discovery collaboration, with the latter adding two novel targets to its drug portfolio. 6 October 2022
Pharnext has executed a financing agreement with Néovacs for around 21 million euros ($21 million), to help develop PXT3003 for Charcot-Marie-Tooth disease type 1A. 4 October 2022
Privately-held Danish dermatology specialist LEO Pharma and Swiss market expansion services provider DKSH have entered into an agreement to bring therapeutic products for skin conditions and thrombosis to patients across Asia. 29 September 2022
Transpire Bio, a USA-based developer of inhaled therapeutics for pulmonary and systemic diseases, today announced a second agreement with Sweden’s Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD). 29 September 2022
Ahmedabad, India-based Torrent Pharmaceuticals has agreed to buy fellow India-based medicinal dermatology company Curatio Health Care for 2,000 crores rupees ($245.22 million), the company said in a stock exchange filing on Tuesday. 27 September 2022
Canada’s Bausch Health and India’s Glenmark Pharmaceuticals have received approval for Ryaltris (olopatadine hydrochloride/mometasone furoate) in Canada. 26 September 2022
The European Commission has approved, under the European Union Merger Regulation, the acquisition of Norgine Europe, together with its subsidiaries (Norgine Group) of the Netherlands by the USA’s Goldman Sachs Group. 16 September 2022
Japanese drugmaker Kyowa Kirin has submitted to broaden the Japanese label for Lumicef (brodalumab), to include the treatment of the uncommon autoimmune disorder palmoplantar pustulosis (PPP). 15 September 2022
Johnson & Johnson has announced that the board of directors has authorized the repurchase of up to $5 billion of the company's common stock. 14 September 2022
Most COVID-19 vaccine contracts signed by the European Commission lacked specific provisions to address supply disruptions, and procurement processes could have been more scrutinized, the European Court of Auditors (ECA) found in a new report released Monday. 13 September 2022
On Friday, the US National Institutes of Health (NIH), the nation’s medical research agency, announced the start of enrollment for a Phase III USA- based clinical trial evaluating tecovirimat (trade name TPOXX) for the treatment of monkeypox. 10 September 2022
German science and technology company Merck KGaA is strengthening its manufacturing capabilities for single-use assemblies, a key technology for the production of COVID-19 vaccines and other lifesaving therapies, by investing more than 130 million euros ($129 million) in Molsheim, France. 8 September 2022
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a new marketing authorization for Lynparza (olaparib) in Great Britain 6 September 2022
Japanese pharma major Takeda has entered into an agreement for the acquisition of its manufacturing site in Asker, Norway, by NextPharma, a contract development and manufacturing organization (CDMO). 6 September 2022
Germany’s Merck KGaA today announced it is investing 160 million euros ($159 million) in a new facility in Darmstadt — the Launch and Technology Center — to further speed up the availability of future pharma medicines for patients in need. 6 September 2022
India’s Minister of State of the Ministry of Science and Technology & Earth Sciences announced India’s first indigenously developed quadrivalent human papillomavirus vaccine (qHPV), Cervavac, for the prevention of cervical cancer. 5 September 2022
The US Food and Drug Administration (FDA) on Friday approved expanded use of Orkambi (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to 3 September 2022
The long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Recordati’s Isturisa (osilodrostat) have been published in The European Journal of Endocrinology. 31 August 2022
Marinus Pharmaceuticals, a pharmaceutical company developing therapeutics to treat seizure disorders, has announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million. 30 August 2022
The US Federal Trade Commission (FTC) announced on Friday that it has approved three omnibus resolutions authorizing compulsory process in investigations, one of which related to mergers, acquisitions, and transactions. 27 August 2022
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024